2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study.
Grebely J, Dore GJ, Altice FL, Conway B, Litwin AH, Norton BL, Dalgard O, Gane EJ, Shibolet O, Nahass R, Luetkemeyer AF, Peng CY, Iser D, Gendrano IN, Kelly MM, Hwang P, Asante-Appiah E, Haber BA, Barr E, Robertson MN, Platt H. Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study. Annals Of Internal Medicine 2022, 175: 1221-1229. PMID: 35939812, DOI: 10.7326/m21-4119.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyLong-term extension studyHCV reinfectionDrug useExtension studyAgonist therapySuccessful treatmentHepatitis C virus (HCV) reinfectionHepatitis C virus infectionBenefits of cureC virus infectionChronic HCV infectionRate of reinfectionUrine drug screeningOngoing drug useClinical trial sitesSubsidiary of MerckHCV infectionCohort studyVirus reinfectionDohme Corp.Treatment completionGenotype 1Virus infectionHigh risk
2019
Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study
Shrestha R, Altice FL, Sibilio B, Ssenyonjo J, Copenhaver MM. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study. Contemporary Clinical Trials 2019, 82: 77-84. PMID: 31229618, PMCID: PMC6639056, DOI: 10.1016/j.cct.2019.06.012.Peer-Reviewed Original ResearchConceptsBio-behavioral interventionHIV risk reductionOpioid-dependent peopleMethadone maintenance programPrEP adherenceHIV transmission risk reductionFirst prospective trialPre-exposure prophylaxisHIV prevention strategiesOngoing drug useRisk reductionBehavioral skills modelProspective trialSecondary outcomesPrimary outcomeRisk reduction outcomesHIV riskWeek 20Prevention strategiesUnmet needDrug useHybrid type IBio-behavioral approachProcess evaluationAdherence
2018
Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S, Dvoriak S, Altice FL. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. Journal Of Substance Use And Addiction Treatment 2018, 87: 1-8. PMID: 29471921, PMCID: PMC5826566, DOI: 10.1016/j.jsat.2018.01.007.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentMethadone maintenance treatmentConcurrent illicit drug useOAT patientsIllicit drug useDrug injectionDrug useAgonist treatmentUse disordersMultivariable logistic regressionConcurrent drug useOngoing drug usePolysubstance use disorderAlcohol use disorderMaintenance treatmentIndependent correlatesBMT programSevere opioidDrug injectingPatientsHealth outcomesTreatment dropoutAlcohol dependenceInjection initiationYounger age
2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Annals Of Internal Medicine 2016, 165: 625-634. PMID: 27537841, DOI: 10.7326/m16-0816.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntiviral AgentsBenzofuransBuprenorphineBuprenorphine, Naloxone Drug CombinationDouble-Blind MethodDrug CombinationsDrug Resistance, ViralFemaleGenotypeHepatitis C, ChronicHumansImidazolesMaleMedication AdherenceMethadoneMiddle AgedOpiate Substitution TreatmentOpioid-Related DisordersQuinoxalinesRecurrenceSubstance Abuse, IntravenousYoung AdultConceptsDeferred-treatment groupOpioid agonist therapyImmediate treatment groupHepatitis C virus infectionC virus infectionElbasvir-grazoprevirDrug useProbable reinfectionAgonist therapyHCV infectionViral recurrenceAdverse eventsVirus infectionChronic HCV genotype 1Double-blind trialGenotype 3 infectionTreatment-naive patientsHCV genotype 1Interferon-free HCV treatmentOngoing drug useVirologic responseHCV therapyHCV treatmentPrimary outcomeGenotype 1
2011
Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone
Fiellin DA, Weiss L, Botsko M, Egan JE, Altice FL, Bazerman LB, Chaudhry A, Cunningham CO, Gourevitch MN, Lum PJ, Sullivan LE, Schottenfeld RS, O'Connor PG. Drug Treatment Outcomes Among HIV-Infected Opioid-Dependent Patients Receiving Buprenorphine/Naloxone. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s33-s38. PMID: 21317592, PMCID: PMC3863630, DOI: 10.1097/qai.0b013e3182097537.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneBuprenorphine/naloxone treatmentOpioid-dependent patientsDrug useOpioid useNaloxone treatmentHIV treatment settingsIllicit opioid useOngoing drug useDrug treatment outcomesNaloxone dosesIllicit opioidsOpioid dependenceOffice visitsProspective studyHIV treatmentRetained patientsTreatment outcomesTreatment retentionPatientsTreatment settingsAddiction treatment processNaloxoneTreatment populationHIV